Mobile App

Google Play Apple Store
Talking TNBC: Advancing Treatment in Triple Negative Breast Cancer: Latest Insights and Clinical Strategies
AMA/ABS/ANCC/ACPE Live Webcast
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. This interactive, live webcast will address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.
Review the activity and claim AMA, ABS, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.


 
Aditya Bardia, MD, MPH, FASCO Aditya Bardia, MD, MPH, FASCO
Associate Professor, Medicine, Harvard Medical School
Attending Physician, Medical Oncology, Massachusetts General Hospital
Dana-Farber/Harvard Cancer Center, Boston, MA

Rita Nanda, MD Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
The University of Chicago Medicine Chicago, IL

20
Supported by an independent educational grant from
Gilead Sciences, Inc.
Mini Module
7826
Talking_TNBC_Webcast_1730x162.png
False
Hematology-Oncology

CookieConsent

Change Settings